List All Breast Cancer Trials

Breast Cancer

 

Premenopausal Early Assessment; ER+, HER2-, FLT (7536a)
Imaging Early Response of ER+, HER2- Breast Cancer To Aromatase Inhibitor (AI) +/- Ovarian Suppression (OS) Therapy With [18F]Fluorothymidine (FLT) PET

Investigator: Hannah M. Linden, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01928186

A Cancer Education Program for Parents (9095)
Enhancing Connections Telephone Program: A Cancer Education Program for Parents

Investigator: Frances Lewis;   Conditions: Breast Cancer, Cervical Cancer, Colon Cancer, Leukemia, Lymphoma, Malignant Neoplasm, Melanoma, Rectal Cancer;    Status: Closed;   Study ID: NCT02129049

Vaccine Therapy for HER2+ Stage IV Breast Cancer
Phase II Study to Evaluate the Development of HER2/neu (HER2)-Specific Memory T Cells After HER2 Peptide-Based Vaccination in Patients with Advanced Stage HER2+ Breast Cancer

Investigator: Lupe Salazar, MD;   Conditions: Breast Cancer;    Status: Closed;   Study ID: NCT01729884

Postmenopausal Early Assessment; ER+, HER2-, FLT (7536b)
Imaging Early Response of ER+, HER2- Breast Cancer To Aromatase Inhibitor (AI) +/- Ovarian Suppression (OS) Therapy With [18F]Fluorothymidine (FLT) PET

Investigator: Hannah M. Linden, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01928186

Pertuzumab in Combination With Herceptin and Vinorelbine for Metastatic or HER2-Positive Breast Cancer (UW12012)
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.

Investigator: Jennifer M. Specht, MD;   Conditions: Breast Cancer;    Status: Temporarily On Hold;   Study ID: NCT01565083

Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer (7952)
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer

Investigator: Larissa Korde, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01276704

F-18 FES PET in Measuring Hormone Expression (7184)
Serial [F-18] fluoroestradiol (FES) PET Imaging to Evaluate Endocrine-Targeted Therapy

Investigator: Hannah Linden, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT02149173

Phase III Paclitaxel + Trastuzumab/Lapatinib (CTSU C40601)
Randomized Phase III Trial of Paclitaxel Combined With Trastuzumab (Herceptin), Lapatinib (Tykerb), or Both as Neoadjuvant Treatment of Her2-Positive Primary Breast Cancer

Investigator: ;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT00770809

Vaccine Therapy for HER2-Negative Stage III-IV Breast Cancer (9140)
A Phase I Trial of the Safety and Immunogenicity of a Multiple Antigen Vaccine (STEMVAC) in HER2 Negative Advanced Stage Breast Cancer Patients

Investigator: Nora Disis, MD;   Conditions: Breast Cancer; Solid Tumors;    Status: Recruiting;   Study ID: NCT02157051

Early Assessment Challenge Grant (7043)
Imaging Early Response of ER+, HER2- Breast Cancer To Aromatase Inhibitor (AI) Therapy

Investigator: David Mankoff, M.D., PhD ;   Conditions: Breast Cancer;    Status: Recruiting

Trastuzumab Emtansine vs. Paclitaxel with Trastuzumab for HER2-positive Breast Cancer (9409)
A randomized Phase II study of adjuvant Trastuzumab emtansine (T-DM1) vs. Paclitaxel in combination with Trastuzumab for Stage I HER2-positive Breast Cancer (ATEMPT Trial)

Investigator: V.K. Gadi, MD, PhD;   Conditions: Breast Cancer; Solid Tumors; HER2-Positive;    Status: Recruiting;   Study ID: NCT01853748

Radiation Therapy for Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery (NSABP B-51 /RTOG 1304)
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Investigator: ;   Conditions: Stage IB Breast Cancer, Stage II Breast Cancer;    Status: Recruiting;   Study ID: NCT01872975

Acupuncture vs. Sham Acupuncture for AI-induced Arthralgias (S1200)
Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women With Early Stage Breast Cancer

Investigator: Julie R. Gralow, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01535066

TDM1 Platelet (7900)
Thrombokinetic Studies of Trastuzumab Emtansine

Investigator: V.K. Gadi, MD, PhD;   Conditions: Breast Cancer;    Status: Open;   Study ID: NCT01816035

Eribulin Mesylate for Previously Treated Metastatic Breast Cancer (8093)
Phase II Trial of Metronomic Eribulin (Halaven) In Pretreated Metastatic Breast Cancer (MBC)

Investigator: Hannah M. Linden, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01908101

SGN-LIV1A for Breast Cancer (13038)
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With LIV-1-Positive Metastatic Breast Cancer

Investigator: Jennifer M. Specht, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01969643

Tissue Collection for ER and Her2 Diagnoses for Patients with Metastatic Breast Cancer (8085)
Quantification of ER and Her2 in Bone Biopsy using a Multiple-Immuno-MRM assay in Metastatic Breast Cancer

Investigator: Julie R. Gralow, MD;   Conditions: Metastatic Breast Cancer;    Status: Recruiting

MPDL3280A + Cobimetinib for Locally Advanced or Metastatic Cancer
A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

Investigator: Laura Chow, MD;   Conditions: Neoplasms;    Status: Closed;   Study ID: NCT01988896

Kadcyla + Pertuzumab vs. Herceptin + Pertuzumab + Taxane for HER2-positive Breast Cancer (UW13051-KAITLIN Trial)
A Randomized, Multicenter, Open-Label, Phase III Trial Comparing Trastuzumab Plus Pertuzumab Plus A Taxane Following Anthracyclines Versus Trastuzumab Emtansine Plus Pertuzumab Following Anthracyclines As Adjuvant Therapy In Patients With Operable Her2 Positive Primary Breast Cancer

Investigator: V.K. Gadi, MD, PhD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01966471

Hormone Therapy w/o Everolimus for Breast Cancer (SWOG 1207)
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer

Investigator: Julie R. Gralow, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01674140

Pertuzumab + Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer (TBCRC 026)
A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast Cancer

Investigator: Jennifer M. Specht, MD;   Conditions: Breast Cancer;    Status: Open;   Study ID: NCT01937117

FDG PET (7159)
FDG PET (Reproducibility Across Centers)

Investigator: Hannah M. Linden, MD;   Conditions: Breast Cancer;    Status: Recruiting

Everolimus, Anastrozole + Fulvestrant for Post-Menopausal Stage IV Breast Cancer
Fulvestrant Alone Versus Fulvestrant and Everolimus Versus Fulvestrant, Everolimus and Anastrozole: A Phase III Randomized Placebo-Controlled Trial in Postmenopausal Patients

Investigator: Julie Gralow, MD;   Conditions: Breast Cancer;    Status: Pending;   Study ID: NCT02137837

MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ (E4112)
Prospective Study of Magnetic Resonance Imaging (MRI) and Multiparameter Gene Expression Assay in Ductal Carcinoma In Situ (DCIS)

Investigator: Habib Rahbar, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT02352883